Aeterna Zentaris: Up on surge in quarterly revenue

COSCIENS Biopharma

25/03/2021 16:04

** U.S.-listed shares of Canadian biopharmaceutical co
 AEZS.O  rise 5.4% to $1.15
    ** Posts Q4 rev of $2.4 mln vs $0.02 mln in 2019
 urn:newsml:reuters.com:*:nGNX8LfY3x
    ** Posts net loss of $1.3 mln vs net loss of $1 mln in 2019,
says wider net loss resulted from increase in total operating
expenses, net finance costs 
    ** In Feb, co announced evaluation and potential development
of an oral prophylactic bacterial vaccine against COVID-19 in
collaboration with Julius-Maximilians-University of Wurzburg
    ** YTD, stock up 172.6%

 (Reporting by Shreyasee Raj in Bengaluru)
 ((Shreyasee.Raj@thomsonreuters.com;))